European Commission approves ZINFORO™ (ceftaroline fosamil) for adult patients with serious skin infections or community acquired pneumonia
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
List view / Grid view
News
Abbott announces CE Mark for highly sensitive testosterone test to measure the hormone at low levels
Abbott announced today CE Marking (Conformité Européenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
U.S. FDA approves Gilead’s Stribild™
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
Clinical experience with Pradaxa® crosses one million patient-years of treatment
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
Key results from new tiotropium studies in COPD and asthma to be presented at ERS 2012
27 August 2012 | By Boehringer Ingelheim
New data to be presented at the Annual Congress of the ERS 2012...
New data from Phase III EMILIA study showed Roche’s trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...
Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...
Merck provides update on cardiovascular development program
26 August 2012 | By Merck
Merck provided an update on the development programs for vorapaxar, extended release niacin/laropirprant and anacetrapib...
New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure
26 August 2012 | By Novartis
Novartis announced results from the Phase II PARAMOUNT study...
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA in COPD
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
Positive Phase 3 clinical study results for Inavir(R) Dry Powder Inhaler for the Prevention of Influenza
22 August 2012 | By Daiichi Sankyo
Inavir® Dry Powder Inhaler significantly reduces the incidence of influenza infection...
Lundbeck appoints new commercial senior vice president and vice president
22 August 2012 | By H. Lundbeck A/S
Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president...
U.S. Food And Drug Administration extends action date for tofacitinib new drug application by three months
21 August 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for tofacitinib...
